Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Anisha M. Patel, Shelby L. Corman, Stephen Chaplin, Karina Raimundo & Robert F. Sidonio. (2019) Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events. Journal of Medical Economics 22:12, pages 1328-1337.
Read now
Read now
Jason P. Swindle, Yaping Xu, Yunming Mu & Paul G. Solari. (2019) Healthcare costs among patients with hemophilia A treated with factor replacement or bypassing agents. Current Medical Research and Opinion 35:8, pages 1433-1440.
Read now
Read now
Ellis J. Neufeld, Robert F. Sidonio$suffix/text()$suffix/text(), Ken O’Day, M. Chris Runken, Kellie Meyer & Jeffrey Spears. (2018) Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States. Journal of Medical Economics 21:8, pages 762-769.
Read now
Read now
Michael Wang, Anissa Cyhaniuk, David L Cooper & Neeraj N Iyer. (2017) Identification of patients with congenital hemophilia in a large electronic health record database. Journal of Blood Medicine 8, pages 131-139.
Read now
Read now
Articles from other publishers (22)
Yilin ChenSpencer J ChengTyler ThornhillPaul SolariSean D Sullivan. (2023) Health care costs and resource use of managing hemophilia A: A targeted literature review. Journal of Managed Care & Specialty Pharmacy 29:6, pages 647-658.
Crossref
Crossref
Cuiyun Qu, Wei Liu, Lingling Chen, Lei Zhang, Feng Xue & Renchi Yang. (2022) Analysis of hospitalization of people with hemophilia—12 years of experience in a single center. Research and Practice in Thrombosis and Haemostasis 6:5, pages e12764.
Crossref
Crossref
Courtney D ThornburgKelly AdamskiKeziah CookMohini VembusubramanianSelvam R SendhilDavid HindsEr ChenJoshua SammonPaul SolariLouis P GarrisonJrJrStacy E Croteau. (2022) Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States. Journal of Managed Care & Specialty Pharmacy 28:4, pages 449-460.
Crossref
Crossref
Eleanor O Caplan, Anisha M Patel, Richard W DeClue, Marina Sehman, Daniel Cornett, Tiffany Fair Shaffer, Karina Raimundo & Brandon T Suehs. (2021) Real-world treatment, clinical outcomes and healthcare resource utilization among persons with hemophilia A by age. Journal of Comparative Effectiveness Research 10:15, pages 1121-1131.
Crossref
Crossref
Arafat ul Alam, Mohammad Karkhaneh, Cynthia Wu & Haowei Linda Sun. (2021) Development and validation of a case definition to identify hemophilia in administrative data. Thrombosis Research 204, pages 16-21.
Crossref
Crossref
Tyler W. Buckner, Iryna Bocharova, Kaitlin Hagan, Arielle G. Bensimon, Hongbo Yang, Eric Q. Wu, Eileen K. Sawyer & Nanxin Li. (2021) Health care resource utilization and cost burden of hemophilia B in the United States. Blood Advances 5:7, pages 1954-1962.
Crossref
Crossref
Stacy E CroteauKeziah CookLamiya SheikhAnita ChawlaJoshua SammonPaul Solari, Benjamin KimDavid HindsCourtney D Thornburg. (2021) Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: an administrative claims analysis. Journal of Managed Care & Specialty Pharmacy 27:3, pages 316-326.
Crossref
Crossref
Mei LuAbiola OladapoYanyu WuSepehr FarahbakhshianBruce Ewenstein. (2021) Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States. Journal of Managed Care & Specialty Pharmacy 27:2, pages 175-185.
Crossref
Crossref
Hanna Ventola, Aino Vesikansa, Jari Jokelainen, Timo Siitonen, Pia Ettala, Outi Laine, Elina Lehtinen, Aino Lepäntalo, Maria Patronen, Anu Partanen, Miika Linna, Tero Ylisaukko‐oja & Riitta Lassila. (2020) Characterisation of healthcare utilisation and cost of haemophilia care in real‐life: A 4‐year follow‐up study in Finland. Haemophilia 27:1.
Crossref
Crossref
Guang-wen Gong, Ying-chun Chen, Peng-qian Fang & Rui Min. (2020) Medical expenditure for patients with hemophilia in urban China: data from medical insurance information system from 2013 to 2015. Orphanet Journal of Rare Diseases 15:1.
Crossref
Crossref
Jenni Firrman, Qizhao Wang, Wenman Wu, Biao Dong, Wenjing Cao, Andrea Rossi Moore, Sean Roberts, Barbara A. Konkle, Carol Miao, LinShu Liu, Dong Li & Weidong Xiao. (2020) Identification of Key Coagulation Activity Determining Elements in Canine Factor VIII. Molecular Therapy - Methods & Clinical Development 17, pages 328-336.
Crossref
Crossref
Melanie Rose, Kewa Gao, Elizabeth Cortez-Toledo, Emmanuel Agu, Alicia A. Hyllen, Kelsey Conroy, Guangjin Pan, Jan A. Nolta, Aijun Wang & Ping Zhou. (2020) Endothelial cells derived from patients’ induced pluripotent stem cells for sustained factor VIII delivery and the treatment of hemophilia A. Stem Cells Translational Medicine 9:6, pages 686-696.
Crossref
Crossref
Guillermo Sánchez-Vanegas, Adriana Linares, Isabel Sarmiento, María H. Solano, Giancarlo Romano & Carlos Castro. (2019) Cost of Patients With Hemophilia A and High-Titer Inhibitors in Colombia. Value in Health Regional Issues 20, pages 164-171.
Crossref
Crossref
J. O'Hara, C. S. Sima, J. Frimpter, F. Paliargues, P. Chu & I. Presch. (2018) Long-term outcomes from prophylactic or episodic treatment of haemophilia A: A systematic review. Haemophilia 24:5, pages e301-e311.
Crossref
Crossref
Jennifer Lyons, Vibha Desai, Yaping Xu, Greg Ridgeway, William Finkle, Paul Solari, Sean Sullivan & Stephan Lanes. (2018) Development and Validation of an Algorithm for Identifying Patients with Hemophilia A in an Administrative Claims Database. Value in Health 21:9, pages 1098-1103.
Crossref
Crossref
Víctor Jiménez-Yuste, María Teresa Álvarez Román, María Eva Mingot-Castellano, Nuria Fernández Mosteirin, María Mareque & Itziar Oyagüez. (2018) Análisis de costes del tratamiento para pacientes con hemofilia A con inhibidor en España. PharmacoEconomics Spanish Research Articles 15:1-4, pages 25-34.
Crossref
Crossref
Gerry Dolan, Gary Benson, Anne Duffy, Cedric Hermans, Victor Jiménez-Yuste, Thierry Lambert, Rolf Ljung, Massimo Morfini & Silva Zupančić Šalek. (2018) Haemophilia B: Where are we now and what does the future hold?. Blood Reviews 32:1, pages 52-60.
Crossref
Crossref
Christina X. Chen, Judith R. Baker & Michael B. Nichol. (2017) Economic Burden of Illness among Persons with Hemophilia B from HUGS Vb: Examining the Association of Severity and Treatment Regimens with Costs and Annual Bleed Rates. Value in Health 20:8, pages 1074-1082.
Crossref
Crossref
Julien Baruteau, Simon N. Waddington, Ian E. Alexander & Paul Gissen. (2017) Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects. Journal of Inherited Metabolic Disease 40:4, pages 497-517.
Crossref
Crossref
R. B. Butler, A. Cheadle, D. J. Aschman, B. Riske, S. Senter, K. M. McLaughlin, G. Young, S. Ahuja & A. D. Forsberg. (2015) National needs assessment of patients treated at the United States Federally‐Funded Hemophilia Treatment Centers. Haemophilia 22:1.
Crossref
Crossref
Patrícia Rocha, Manuela Carvalho, Manuela Lopes & Fernando Araújo. (2015) Costs and utilization of treatment in patients with hemophilia. BMC Health Services Research 15:1.
Crossref
Crossref
T. Ohmori, H. Mizukami, K. Ozawa, Y. Sakata & S. Nishimura. (2015) New approaches to gene and cell therapy for hemophilia. Journal of Thrombosis and Haemostasis 13, pages S133-S142.
Crossref
Crossref